Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer.

Abstract

Between 1983 and 1987 25 patients with invasive bladder cancer (16 stage tumor 3 (T3) and nine stage T4) were treated with intraarterial cisplatin and concurrent radical radiation (20/25) or intraarterial cisplatin, concurrent preoperative radiation, and cystectomy (5/25). One patient died from treatment-related toxicity. Other toxicities have been what one would expect from the individual treatment modalities except for a sensory sacral root neuropathy in 11 of 24 (46%) patients. Twenty-three of 24 (96%) patients achieved a complete response (CR) and the projected actuarial 2-year survival is 90%. Only one of the 23 complete responders has had an invasive local recurrence. The excellent complete local response and survival rates achieved warrant further study of the combination of intraarterial cisplatin and radiation as a bladder-preserving strategy.

Selective bladder preservation with curative intent for muscle‐invasive bladder cancer: A contemporary review

“…However, IAC results in a unique complication, pelvic neuropathy, with an incidence of 20-30%. 29,30,33 In addition, the complexity of the procedure, which involves intervention radiologists, limits the prevalence of IAC worldwide.…”

A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to W eekly Cisplatin A lone Combined with Concurrent Radiotherapy for Locally Advanced Cervical Cancer

“…Concurrent chemoradiation has been proved to achieve more favorable clinical outcome in many organs, including bladder, head and neck malignancies (16,17). With concurrent chemoradiation treatment of uterine cervical cancer, cisplatin, 5-FU and hydroxyurea have been commonly investigated (10～12,18).…”

Cisplatin plus Radiotherapy in Bladder Cancer

“…Although 48% of the patients in the MGH series showed a complete response after upfront chemotherapy, the local complete response after additional irradiation (40 Gy) plus cisplatin was only 67%. At the University of Florida, two courses of MCV chemotherapy were followed by an irradiation scheme identical to that of the National (EAPAN et al 1989). The drug (60-120 mg/m 2 ) was administered via both iliac arteries over 2 h. Three courses were performed at 3-week intervals prior to and concurrent with irradiation.…”